ArticleOncogene2006
An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen.
Article in Oncogene, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 281 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
281 citing papers in PubMed, 3 syntheses or guidelines pooled it, 584 citations in OpenAlex.
- mRNA ratios of AR to ESR1 and PGR distinguish breast cancer subtypes based on public datasets and experimental models.Scientific reports · 2025Pooled it
- The Lipocalin Apolipoprotein D Functional Portrait: A Systematic Review.Frontiers in physiology · 2021Pooled it
- Prognostic value of androgen receptor in triple negative breast cancer: A meta-analysis.Oncotarget · 2016Pooled it
- Trial
- Molecular apocrine tumours in EORTC 10994/BIG 1-00 phase III study: pathological response after neoadjuvant chemotherapy and clinical outcomes.British journal of cancer · 2019Trial
- Prognostic and predictive value of androgen receptor expression in postmenopausal women with estrogen receptor-positive breast cancer: results from the Breast International Group Trial 1-98.Breast cancer research : BCR · 2019Trial
- Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2018Trial
- Heat shock protein 27 and gross cystic disease fluid protein 15 play critical roles in molecular apocrine breast cancer.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Trial
- Androgen receptor expression predicts beneficial tamoxifen response in oestrogen receptor-α-negative breast cancer.British journal of cancer · 2016Trial
- The effects of soy supplementation on gene expression in breast cancer: a randomized placebo-controlled study.Journal of the National Cancer Institute · 2014Trial
- Gross cystic disease fluid protein 15 (GCDFP-15) expression in breast cancer subtypes.BMC cancer · 2014Trial
- Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2013Trial
- Beyond the canonical view: steroid receptor network plasticity and mechanosensitive chromatin integration in breast cancer.NAR cancer · 2026Review
- The clinical relevance of apocrine morphology in breast cancer depends on the estrogen receptor status.NPJ breast cancer · 2026Article
- Chemotherapy is associated with differential survival outcomes in apocrine carcinoma: A nationwide cohort study from the Japanese National Clinical Database-Breast Cancer Registry.Breast (Edinburgh, Scotland) · 2026Observational
- An Update on the Role of Androgens and Androgen Receptor in Triple-Negative Breast Cancer.Cells · 2026Review
- MUCL1 in triple-negative breast cancer: a novel marker associated with the luminal androgen receptor subtype.Breast cancer research : BCR · 2026Article
- Clinicopathological observation and initial exploration of characteristic biomarkers in breast apocrine carcinoma.Journal of translational medicine · 2026Article
- Spotting a unicorn: spatial transcriptome analysis of the eyelid reveals gene regulatory networks enriched in Moll glands.Briefings in bioinformatics · 2026Article
- Spatial organization of the tumor immune microenvironment in LAR+ triple-negative breast cancer.Frontiers in immunology · 2026Article
221 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Little is known of the underlying biology of estrogen receptor-negative, progesterone receptor-negative (ER(-)/PR(-)) breast cancer (BC), and few targeted therapies are available. Clinical heterogeneity of ER(-)/PR(-) tumors suggests that molecular subsets exist. We performed genome-wide expression analysis of 99 primary BC samples and eight BC cell lines in an effort to reveal distinct subsets, provide insight into their biology and potentially identify new therapeutic targets. We identified a subset of ER(-)/PR(-) tumors with paradoxical expression of genes known to be either direct targets of ER, responsive to estrogen, or typically expressed in ER(+) BC. Differentially expressed genes included SPDEF, FOXA1, XBP1, CYB5, TFF3, NAT1, APOD, ALCAM and AR (P<0.001). A classification model based on the expression signature of this tumor class identified molecularly similar BCs in an independent human BC data set and among BC cell lines (MDA-MB-453). This cell line demonstrated a proliferative response to androgen in an androgen receptor-dependent and ER-independent manner. In addition, the androgen-induced transcriptional program of MDA-MB-453 significantly overlapped the molecular signature of the unique ER(-)/PR(-) subclass of human tumors. This subset of BCs, characterized by a hormonally regulated transcriptional program and response to androgen, suggests the potential for therapeutic strategies targeting the androgen signaling pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.